6th Annual

Inflammation Inhibitors

Small Molecule and Macrocyclic Approaches

April 21-22, 2015  


This conference features medicinal chemistry-focused case studies of small molecule and macrocyclic drug candidates progressing in pre-clinical and clinical development. In addition to presentations highlighting the well-known kinase inhibitors progressing in the pipeline, drug leads directed against ‘newer’ kinases and non-kinase targets will be a part of the meeting. Connections between inflammation and other disease processes will also be explored. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of CHI's larger Drug Discovery Chemistry event.


Speakers were great and presented valuable data. Comprehensive conference and
overview of most current inflammation targets and therapies.

Tina T., Associate Scientist, Biogen Idec

Preliminary Agenda

Plenary Keynote

Chemotype Coverage in Fragment, Phenotypic, & Deorphanization Screens

Brian K. Shoichet, Ph.D., Professor, Department of Pharmaceutical Chemistry, University of California, San Francisco


The Discovery of First-in-Class Drugs: Successes of Target-based and Phenotypic Approaches

Jörg Eder, Ph.D., Executive Director, Novartis Institutes for BioMedical Research

New Targets Emerging from Genetics: Time to Look Back, Move Forward with Phosphatases? (PTPN22)

Nunzio Bottini, M.D., Ph.D., Associate Professor, Division of Cell Biology, La Jolla Institute for Allergy and Immunology

The Discovery of APD334, a Selective S1P1 Functional Antagonist

Robert Jones, Ph.D., Associate Vice President, Medicinal Chemistry, Arena Pharmaceuticals

A CUL4CRBN E3 Ubiquitin Ligase Modulator for Combating Autoimmune Disease

Ying Ye, Ph.D., Director, Clinical Pharmacology, Translational Development, Celgene


Identification of RORc Inverse Agonists with Favorable in vivo PK and in vivo Suppression of IL-17

Benjamin Fauber, Ph.D., Scientist, Small Molecule Drug Discovery, Genentech

Novel Small Molecule Immunomodulators that Target Toll-Like Receptors

Hang Hubert Yin, Ph.D., Associate Professor, Chemistry and Biochemistry & BioFrontiers Institute, University of Colorado


Discovery of a New Series of Small Molecule Bruton’s Tyrosine Kinase Inhibitors

Mark Sabat, Ph.D., Principal Scientist, Medicinal Chemistry, Takeda

Development of a Bruton’s Tyrosine Kinase Inhibitor, ONO-4059: Potential Treatment for Rheumatoid Arthritis & Systemic Lupus Erythematosus

Yuko Ariza, Ph.D., Associate Project Leader, Exploratory Research Laboratories II, Ono Pharmaceutical Co.

Discovery and Design of BTK Inhibitors

Bill Thomas, Ph.D., Scientist III, Medicinal Chemistry, Pharmacyclics

PPIP5K 1 and 2: A New Class of Small Molecule Kinases for Anti-Inflammatory Drug Development

Huanchen Wang, Ph.D., Senior Investigator, Signal Transduction, National Institute of Environmental Health Sciences, NIH

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com